Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01763996 · ClinicalTrials.gov registry record · Phase 4

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

A Phase 4 study of Coronary Artery Disease, sponsored by Takeda.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01763996: Completed Phase 4 study of Coronary Artery Disease, sponsored by Takeda.

NCT01763996 is a Phase 4 study of Coronary Artery Disease that has completed, run by Takeda. The registered enrollment target is 30 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01763996, a Phase 4 study of Coronary Artery Disease, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effect of febuxostat on coronary artery flow in patients with coronary artery disease.

Primary Outcome

Coronary artery flow was measured using magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip exercises. Data at the end of each treatment period was combined for the febuxostat and the placebo arms. A positive change from Baseline indicates improvement.

Conditions Studied

Coronary Artery Disease

Interventions

  • DRUG Febuxostat
  • DRUG Febuxostat placebo

Study Locations (1)

Maryland

  • - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-05
Est. Completion 2015-04
Phase Phase 4
Takeda

408 total trials

What the finished NCT01763996 record still lists

NCT01763996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Febuxostat is the first listed.

NCT01763996 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01763996 about?

NCT01763996 is a clinical study titled "The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina". The purpose of this study is to assess the effect of febuxostat on coronary artery flow in patients with coronary artery disease.

What is the current status of trial NCT01763996?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2013-05. Estimated completion is 2015-04.

What conditions does trial NCT01763996 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT01763996?

The interventions under investigation include: Febuxostat (DRUG), Febuxostat placebo (DRUG).

Who is sponsoring clinical trial NCT01763996?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01763996 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01763996's enrollment target sits among peer trials

30 198th of 219 higher than 17 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01763996, the US trial registry maintained by the National Library of Medicine. NCT01763996 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.